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IntroductIon
Congenital long QT syndrome (LQTS) is 
clinically characterized by the occurrence 
of syncope due to polymorphic ventricular 
tachycardia (torsades de pointes), associ-
ated to delayed cardiac repolarization that 
is reflected by a prolongation of the QT 
interval on the ECG (Webster and Berul, 
2008). Thus far, 13 genes coding for ion 
channel subunits and ion channel regula-
tory proteins have been found mutated in 
patients and families with LQTS (Schwartz 
et al., 2009). The estimated prevalence of 
LQTS in the general population is reported 
to be in the range of 1:7000–1:2000 (0.01–
0.05%), without any significant ethni-
cal disparity (Roden and Spooner, 1999; 
Tester et al., 2006; Schwartz et al., 2009). 
Different research groups from many coun-
tries have reported similar data or cited the 
same sources (Roden and Spooner, 1999; 
Tester et al., 2006; Schwartz et al., 2009). 
Recently, two original studies reported a 
high prevalence of LQTS founder muta-
tions in the Finnish and Norwegian popu-
lation (Berge et al., 2008; Marjamaa et al., 
2009). In Finland, it was concluded that 1 
out of 250 individuals (0.4%) carry a LQTS 
founder mutation (Marjamaa et al., 2009). 
In Norway, the prevalence of LQTS muta-
tion carriers was estimated to be close to 
1%, which is a prevalence that is the high-
est documented worldwide (Berge et al., 
2008). These findings are of clear interest 
to researchers and clinicians since they 
may not be only relevant for the Finnish 
and Norwegian populations, but may also 
give some important clues about the actual 
worldwide distribution of genetic variants 
predisposing to cardiac arrhythmias. In a 
study looking at variants in KCNQ1 in a 
subgroup with the longest QTc interval 
(403–443 ms) from French general popu-
lation of 100 non-related and non-treated 
individuals from the DESIR cohort, two 
new mutations in KCNQ1 were found 
(Gouas et al., 2004). This study suggests that 
such low-penetrant variants might be found 
with 2% frequency within one “healthy” 
cohort after screening of one only one gene 
of interest. As it can be seen, there are clear 
discrepancies in estimations of LQTS muta-
tion prevalence depending on the sources.
Long QT syndrome is considered as a 
Mendelian arrhythmic disorder which is 
transmitted mainly in an autosomal domi-
nant mode of inheritance (Priori et al., 2008). 
Thus, one should be able to apply the basic 
concepts of genetics such as Mendel’s law 
for families and Hardy–Weinberg equation 
for population in equilibrium. Hereafter, we 
analyze and interpret published data and 
our own results to estimate the prevalence 
of LQTS using different approaches.
HypotHesIs 1: congenItal lQts Is a 
rare dIsease
We postulate that there is no obvious 
reason to consider that the populations 
in which the distribution of LQTS muta-
tions has been studied are not in genetic 
equilibrium. Thus, we can use the Hardy–
Weinberg equation stating that, in such a 
population, the sum of mutated and nor-
mal alleles frequencies is 1 (i.e., p + q = 1, 
where “p” – frequency of normal allele, “q” 
– cumulated frequencies of mutant alleles; 
Vogel and Motulsky, 1986). It follows that 
(p + q)2 = 1, provided 0 ≤ p ≤ 1; and 0 ≤ q ≤ 1; 
and p2 + 2pq + q2 = 1. For a dominant dis-
ease with a sizable probability of survival 
of compound heterozygous subjects, the 
number of healthy individuals is p2, and the 
maximum number of mutation carriers (or 
affected individuals) is (2pq + q2).
For our calculations, we assume the 
prevalence of diagnosed LQTS using aver-
aged published data from population 
without clear founder effect as 1:4000 
(2.5 × 10−4). The penetrance of LQTS was 
reported to range between 0.25 (Priori et al., 
1999) and 0.7 (Goldenberg et al., 2008), 
but could be higher, i.e., 0.88, for specific 
mutations (Brink et al., 2005). Considering 
an average penetrance of 0.5, the preva-
lence of carriage of at least 1 mutant allele 
should amount to about 5 × 10−4. For rare 
dominant diseases, p tends to 1, and in this 
case, 2pq → 2q, and (2pq + q2) → 2q. It can 
therefore be stated that 2q + q2 = 5 × 10−4; 
and simple arithmetic calculations gives us 
2q = 5 × 10−4, and q2 = 6.25 × 10−8. In such 
a case, the frequency of double-mutation 
carriers in LQTS cohorts can be calculated 
as (q2/2q + q2) = (q/2 + q2) and would equal 
1.25 × 10−4, or 0.0125% within the group 
of interest. This calculation looks trivial 
and consistent, but here one is facing with 
a strong discrepancy between such an 
expected frequency of double-mutation 
carriers and data obtained from large stud-
ies (Westenskow et al., 2004; Fodstad et al., 
2006; Daubert et al., 2007). As a matter of 
fact, the prevalence of compound heterozy-
gous has been reported to amount from 4 
to 7.9% in several cohorts of LQTS patients 
(Splawski et al., 2000; Westenskow et al., 
2004; Itoh et al., 2010), and the carrying 
of three independent mutations was found 
in about 1% of genotype-positive patients 
(Kapplinger et al., 2009). These observa-
tions are in accordance with our own find-
ings. Since 1998, we have analyzed 120 index 
patients with inherited arrhythmic syn-
dromes of Russian origin and have found 
about 7% of double-heterozygous probands 
among the LQTS families. Incomplete clini-
cal diagnostics of LQTS or inaccuracies of 
our calculations cannot explain satisfac-
torily this ∼300- to 600-fold difference 
between expected and observed rates. This 
discrepancy could mean, however, that the 
actual prevalence of LQTS varies among 
population and is largely underestimated.
HypotHesIs 2: tHere Is no relIable 
data about lQts prevalence
It is possible to estimate the prevalence of 
disease-causing mutations assuming that the 
observed number of compound heterozy-
gous in LQTS cohorts is correct. Indeed, 
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LQTS genes usually show a more severe 
clinical phenotype (Bezzina et al., 2003; 
Miller et al., 2004; Westenskow et al., 2004; 
Fodstad et al., 2006; Richter and Brugada, 
2006; Daubert et al., 2007), and it is diffi-
cult to misdiagnose them. Ex hypothesis, 
the population is in equilibrium (Hardy–
Weinberg ratio holds true) but the frequency 
of LQTS is unknown. If we assume that the 
mutation events in different alleles are inde-
pendent, the prevalence of carriers with an 
additional mutation (double event) within 
a LQTS population should be similar to the 
prevalence of one-mutation carriers (single 
event). The prevalence of double-mutation 
carriers among LQTS patients is on aver-
age 0.07 (see above). This result suggests 
that about 7% of individuals in population 
worldwide may carry genetic alterations 
in LQTS genes with potential clinical sig-
nificance. Here, the conclusion would be the 
same – the prevalence of LQTS genotype is 
currently strongly underestimated. We do 
not find any strong argument against this 
conclusion, but it may seem to be too much 
to be true. However, a very recent report 
(Refsgaard et al., 2012) provides strong sup-
port to this concept. Analyzing the data of 
the NHLBI GO Exome Sequencing Project 
looking at missense and nonsense genetic 
variants in a North European control cohort, 
it was estimated that prevalence of unique 
LQTS-associated variants in 5298 individual 
studied is 1:31, and the prevalence of LQTS 
variants found in at least three alleles is 
about 1:37 (Refsgaard et al., 2012). In total, 
this corresponds to 6% of the alleles of this 
control cohort, not including large inser-
tion/deletion and intronic splice variants.
We have no clear way how to solve the 
discrepancies resulting from these calcula-
tions. These observations suggest conclu-
sions and raise questions that need to be 
solved.
1.  The numbers, which we accept as being 
the prevalence of LQTS, represents the 
disease “detectability”; whereas the fre-
quency of cardiac channelopathies, in 
particular LQTS, is underestimated. 
This prevalence may run up to several 
percents, not only in specific ethnic 
groups, but also worldwide.
2. There are gene variants, found in 
patients with inherited arrhythmic syn-
dromes, changing biophysical proper-
ties of ion channels such as p.V1951L 
and p.P2006L in SCN5A gene, p.T8A 
in KCNE2, and p.D85N in KCNE1, but 
which are considered as polymorphisms 
because of their frequencies in control 
groups close to 1% (Sesti et al., 2000; 
Nishio et al., 2009; Shinlapawittayatorn 
et al., 2011). The list of such variants 
could be continued. It seems to us, that 
one should be very careful to consider 
such variants as having no consequence 
taking into account the probability of 
high prevalence of LQTS alleles and low 
disease penetrance. Furthermore, their 
impact could vary in the presence of ion 
channel gene mutations in the second 
allele or in reaction to a given drug, 
which may lead to drug-induced LQTS.
3.  Cost of DNA diagnostics is decreasing 
rapidly from year to year allowing large 
scale screening technologies of carriers 
of non-malignant genetic variants, with 
so-called form fruste of LQTS, who are 
unaware of their status. Indeed, there 
are many factors including a long list 
of drugs and clinical situations that can 
trigger life-threatening episodes in such 
patients.
The accurate estimation of LQTS prev-
alence is not only of academic interest. 
Current researches in human genetics tend 
to increase the amount of genes to ana-
lyze, and the size of control group (usually, 
healthy or untested individuals) to test the 
rarity of given variant. At that rate, a variant 
found in a control group of several hun-
dred volunteers can be easily classified (or 
re-classified) as non-pathogenic. It is clear 
that next generation sequencing techniques 
are providing us a more comprehensive data 
and new insights about genetic bases of 
monogenic disorders. One has to say that, 
at this stage, the analyses and interpretation 
of such data are still very complex.
Finally, here three unanswered questions 
that we would like to raise:
1. What would be an optimal combina-
tion of methods and criteria to use for 
an accurate and predictive characteri-
zation of gene variants in patients with 
channelopathies?
2.  What would be the best DNA diagno-
stics strategy for patients with suspected 
LQTS, and how we can deal with fun-
ctional variant/mutation carriers?
3.  Should congenital LQTS, and inherited 
arrhythmias in general, still be conside-
red as monogenic disorders?
We are convinced that realistic solutions 
to these questions will provide an invalu-
able assistance to cardiologic practice and 
genetic counseling.
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